Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

TTRX

Turn Therapeutics Inc

9.71

Aug 04 • 2:32 PM ET +0.87 (9.84%)

Healthcare Biotechnology USA Micro NASD

Peers: AARD AGEN CNTB GALT GUTS IMUX KZIA NTHI SPRO VRCA

| Held by: VTI IWC

Scroll to Statements

Index	-
Market Cap	289.25M
Enterprise Value	284.04M
Income	-3.84M
Sales	0.00M
Book/sh	0.21
Cash/sh	0.38
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	2
IPO	Oct 08, 2025

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	47.28
P/C	25.78
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	2.23
Current Ratio	2.23
Debt/Eq	0.98
LT Debt/Eq	0.97
Option/Short	No / Yes

EPS (ttm)	-0.18
EPS next Y	-0.32
EPS next Q	-0.02
EPS this Y	25.00%
EPS next Y	-255.56%
EPS next 5Y	-
EPS past 3/5Y	29.26% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-37.24%
Sales Y/Y TTM	-
EPS Q/Q	-193.75%
Sales Q/Q	-
Earnings	May 11 AMC
EPS/Sales Surpr.	-50.00% -

Insider Own	63.78%
Insider Trans	0.00%
Inst Own	2.81%
Inst Trans	30.56%
ROA	-
ROE	-
ROIC	-31.77%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	7.76%
SMA50	32.73%
SMA200	106.14%
Trades

Shs Outstand	29.79M
Shs Float	10.79M
Short Float	0.54%
Short Ratio	0.74
Short Interest	0.06M
52W High	26.50 -63.36%
52W Low	2.57 277.81%
Volatility	7.90% 11.84%
ATR (14)	0.81
RSI (14)	62.09
Beta	-
Rel Volume	0.49
Avg Volume	78.05K
Volume	31,216

Perf Week	26.10%
Perf Month	26.27%
Perf Quarter	161.73%
Perf Half Y	132.30%
Perf YTD	146.45%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	26.00
Prev Close	8.84
Price	9.71
Change	9.84%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-29-25	Initiated	D. Boral Capital	Buy	$8

Jul-28-26 08:01AM	Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026 (Business Wire)
Jul-08-26 07:17AM	Turn Therapeutics stock jumps on AD data and trial expansion (Clinical Trials Arena) -5.36%
Jul-07-26 08:05AM	Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis (Business Wire) +26.27%
Jul-06-26 04:01PM	Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis (Business Wire) +8.01%
Jun-01-26 08:30AM	Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis (Business Wire) +21.73%
08:05AM	Loading…
May-27-26 08:05AM	Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model (Business Wire)
May-19-26 08:01AM	Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026 (Business Wire) -7.14%
May-18-26 08:05AM	Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead (Business Wire) +20.99%
May-11-26 04:05PM	Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates (Business Wire)
Mar-31-26 04:05PM	Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates (Business Wire)
Mar-24-26 08:00AM	Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group (Business Wire)
Mar-02-26 01:08AM	Turn Therapeutics Talks GX-03 Phase II Eczema Data Timeline and Non-Systemic Topical Strategy (MarketBeat)
Feb-17-26 08:00AM	Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs (Business Wire) -8.83%
Feb-09-26 08:00AM	Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences (Business Wire)
Jan-12-26 08:05AM	Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference (Business Wire) -8.44%
04:05PM	Loading…
Jan-07-26 04:05PM	Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors (GlobeNewswire)
Dec-29-25 07:52AM	Here Are Mondays Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More (24/7 Wall St.) +14.60%
Nov-13-25 08:00AM	Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire) -7.05%
Nov-11-25 04:05PM	Turn Therapeutics CEO, Bradley Burnam, Speaks with Former Director of the Centers for Disease Control and Prevention Dr. Robert Redfield, M.D. (GlobeNewswire) -6.05% +13.40%
08:00AM	Turn Therapeutics' GX-03 Technology Named as One of "Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment" by Patient Care Online Magazine (GlobeNewswire)
Nov-04-25 05:07PM	Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate Communications (GlobeNewswire)
Oct-30-25 07:30AM	Turn Therapeutics Enters Global Supply, Development, and License Agreement with Leading Medical-Surgical Product Manufacturer and Distributor Medline (GlobeNewswire)
Oct-22-25 08:00AM	Turn Therapeutics Provides Shareholder Update Highlighting Continued Execution Across Clinical and Strategic Milestones (GlobeNewswire) -11.81%
Oct-20-25 08:22AM	Turn Therapeutics Launches Webinar Series for Ongoing Shareholder Engagement, First Session October 22, 2025 (GlobeNewswire)
Oct-15-25 08:00AM	Turn Therapeutics Appoints Dr. Kent Kester to Board of Directors (GlobeNewswire) -14.57%
Oct-14-25 12:07PM	Turn Therapeutics Appoints Arthur Golden to Board of Directors (GlobeNewswire) -8.29%
Oct-08-25 08:00AM	Turn Therapeutics to Commence Trading Today on Nasdaq (GlobeNewswire)

Turn Therapeutics, Inc. is a pharmaceutical and medical device development company. Its primary development programs focus on dermatological diseases. The company was founded by Bradley Burnam on January 6, 2015 and is headquartered in Westlake Village, CA.

FounderMr. Bradley E. Burnam

Interim CFOMr. Zuraiz Chaudhary

Chief Medical Officer & DirectorDr. Neilesh Shailesh Ghodadra M.D.

ControllerMohammed Zubair

M.D.Dr. Stephen M. Hahn FASTRO

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chaudhary Zuraiz	See Remarks	Dec 12 '25	Buy	3.50	2,500	8,750	12,500	Dec 12 06:00 PM
GOLDEN ARTHUR F	Director	Nov 24 '25	Buy	3.44	9,868	33,946	60,602	Nov 25 09:00 PM
GOLDEN ARTHUR F	Director	Nov 21 '25	Buy	2.87	20,532	58,927	50,734	Nov 24 07:13 AM
Chaudhary Zuraiz	See Remarks	Nov 20 '25	Buy	2.61	1,450	3,784	9,000	Nov 21 05:43 PM
Chaudhary Zuraiz	See Remarks	Nov 21 '25	Buy	3.29	1,000	3,290	10,000	Nov 21 05:43 PM
Chaudhary Zuraiz	See Remarks	Nov 17 '25	Buy	3.62	2,500	9,050	7,550	Nov 17 09:23 PM
Chesed Abraham	Board Observer	Oct 23 '25	Buy	4.60	14,286	65,716	1,447,268	Oct 29 08:43 PM
Chaudhary Zuraiz	See Remarks	Oct 23 '25	Buy	4.95	5,050	24,998	5,050	Oct 23 09:03 PM
GOLDEN ARTHUR F	Director	Oct 23 '25	Buy	4.95	20,202	100,000	30,202	Oct 23 09:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TTRX

Turn Therapeutics Inc

Upgrade your Finviz experience